Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Home
2022
February
Monthly Archives: February 2022
Valneva awarded up to £20m by Scottish Enterprise to advance vaccine...
28th February 2022
Code Bio to collaborate with Takeda to develop gene therapies for...
28th February 2022
Cantex to expand development of drug for COVID-19 and other inflammatory...
28th February 2022
Researchers identify promising drug for treating serious COVID-19 complication in children
28th February 2022
FDA approves treatment for wider range of patients with heart failure
25th February 2022
BioNTech and Medigene announce global collaboration to advance T cell receptor...
25th February 2022
Renaissance BioScience Corp. announces new patents for acrylamide-reducing yeast technology
24th February 2022
UK Aid funding for research to develop Zika virus vaccine
22nd February 2022
ACG Capsules launches campaign to promote problem-free pharmaceutical production
22nd February 2022
Axcella Therapeutics granted FDA Fast Track Designation for AXA1125 in NASH
17th February 2022
1
2
3
Page 1 of 3
News
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion...
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...